Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion

    Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech
   International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals

PR Newswire

CHICAGO, Jan. 31, 2013

CHICAGO, Jan. 31, 2013 /PRNewswire/ --Zacks Equity Research highlights
Smithfield Foods, Inc. (NYSE:SFD) as the Bull of the Day and Logitech
International (Nasdaq:LOGI) as the Bear of the Day. In addition, Zacks Equity
Research provides analysis on Sanofi (NYSE:SNY), Isis Pharmaceuticals Inc.
(Nasdaq:ISIS) and Aegerion Pharmaceuticals Inc. (Nasdaq:AEGR).


Full analysis of all these stocks is available at

Here is a synopsis of all five stocks:

Bull of the Day:

Started in 1936 as a small family owned packing plant in Smithfield, VA,
Smithfield Foods, Inc. (NYSE:SFD) is now world's largest pork processor (28%
market share) and hog producer (14% market share).

Smithfield Foods conducts its business through two groups, the Meat Processing
Group and the Hog Production Group. Some of the popular brands include Eckrich
sausage, Farmland bacon, Armour pepperoni and Healthy Ones prepared meals.

Smithfield had suffered losses in 2008 and 2009 as a result of higher grain
costs and oversupply of hogs. However the company recovered nicely in fiscal
2011 and posted record high revenue in fiscal 2012.

Of late, the company has put a lot of efforts in improving the packaging and
producing healthier choices for consumers using lean protein and natural
ingredients. Smithfield is also increasing its focus on consumer convenience
by introducing more ready-to-heat/ready-to-eat foods.

Bear of the Day:

Founded in 1981, Logitech International (Nasdaq:LOGI) is a Swiss public
company listed on the SIX Swiss Exchange and on the Nasdaq Global Select

The company is a global leader in peripherals for personal computers and other
digital platforms. Some of the company's popular products are computer mice
(world's largest producer), keyboards and speakers. Other products include
trackballs, interactive gaming controllers, multimedia speakers, headsets, web
cameras and lap desks. The company operates through two major business
segments: peripherals (86% of 2012 total revenue) and video conferencing.

LOGI released its results for the third quarter of its fiscal 2013 on January
24, 2013. Sales for the quarter were down 14% year-over-year. Net loss for
quarter was $195 million ($1.24 per share) compared with net income of $55
million ($0.32 per share) in prior-year quarter. Gross margin for the quarter
was 34.2%, down from 36.2% in the same quarter one year ago.

Latest Posts on the Zacks Analyst Blog:

FDA Nod for Isis/Sanofi's Kynamro

The US Food and Drug Administration (FDA) recently approved Kynamro
(mipomersen sodium) injection developed by Genzyme, a Sanofi (NYSE:SNY) and
Isis Pharmaceuticals Inc. (Nasdaq:ISIS). Kynamro is approved for cholesterol
management in patients suffering from homozygous familial hypercholesterolemia

The FDA's decision did not come as a surprise. In Oct 2012, the US regulatory
body's Endocrinologic and Metabolic Drugs Advisory Committee had voted in
favor of approving Kynamro. The approval of the drug triggers a $25 million
milestone payment from Sanofi.

We note that Kynamro carries a Boxed Warning citing the risk of hepatic
toxicity. Kynamro is available only through a Risk Evaluation and Mitigation
Strategy (REMS) because of the risk of hepatic toxicity.

We believe this safety concern might to an extent undermine the commercial
potential of the drug. Aegerion Pharmaceuticals Inc.'s (Nasdaq:AEGR) Juxtapid
(lomitapide) for HoFH patients, which was recently launched, would also eat
into Kynamro sales.

Meanwhile, Sanofi is working on re-examining the negative decision related to
Kynamro from the advisory board of the European Medicines Agency (EMA). In Dec
2012, the Committee for Medicinal Products for Human Use (CHMP) had
recommended against the approval of Kynamro.

We are encouraged with Kynamro's approval in the US which validates the
antisense technology. Isis Pharma has several other candidates in the pipeline
based on this technology.

Isis Pharma currently carries a Zacks Rank #3 (Hold).

Get the full analysis of all these stocks by going to

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are
likely to outperform (Bull) or underperform (Bear) the markets over the next
3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from
Zacks Equity Research about the latest news and events impacting stocks and
the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous analyst coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives them keen
insights to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today by visiting

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In
short, it's your steady flow of Profitable ideas GUARANTEED to be worth your
time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance
numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.